CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) insider Dennis D. Kim sold 7,781 shares of the firm’s stock in a transaction that occurred on Thursday, April 13th. The shares were sold at an average price of $8.98, for a total transaction of $69,873.38. Following the completion of the sale, the insider now directly owns 20,000 shares in the company, valued at $179,600. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of CymaBay Therapeutics stock opened at $9.84 on Wednesday. The company’s fifty day simple moving average is $8.66 and its two-hundred day simple moving average is $6.15. CymaBay Therapeutics, Inc. has a 12-month low of $1.67 and a 12-month high of $10.25. The company has a market cap of $957.33 million, a P/E ratio of -8.13 and a beta of 0.27.

CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) last announced its quarterly earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). During the same quarter in the previous year, the firm posted ($0.34) EPS.  Analysts predict that  CymaBay Therapeutics, Inc. will post -0.93 EPS for the current fiscal year.

A number of research analysts have commented on CBAY shares. SVB Leerink increased their price target on shares of CymaBay Therapeutics from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Wednesday, February 8th. Piper Sandler increased their price target on shares of CymaBay Therapeutics from $12.00 to $19.00 and gave the company an “overweight” rating in a research report on Sunday, January 29th. Raymond James raised their target price on shares of CymaBay Therapeutics from $14.00 to $17.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 17th. Oppenheimer upped their price target on shares of CymaBay Therapeutics from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Tuesday, March 7th. Finally, HC Wainwright increased their price target on shares of CymaBay Therapeutics from $10.00 to $12.00 in a research report on Friday, March 17th. One analyst  has rated the stock with a hold rating, seven have assigned  a buy rating and one  has issued  a strong buy rating to the company. According to data from MarketBeat.com, the company  has an average rating of “Buy” and a consensus price target of $13.50.

A number of institutional investors and hedge funds have recently made changes to their positions in CBAY. Saturn V Capital Management LLC purchased a new position in shares of  CymaBay Therapeutics in the 4th quarter valued at approximately $5,718,000.  Millennium Management LLC lifted its stake in shares of  CymaBay Therapeutics by 27.1% in the 2nd quarter. Millennium Management LLC now owns 3,015,496 shares of the biopharmaceutical company’s stock valued at $8,896,000 after purchasing an additional 642,796 shares during the period.  Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of  CymaBay Therapeutics in the 3rd quarter valued at approximately $2,087,000.  UBS Group AG lifted its stake in shares of  CymaBay Therapeutics by 1,347.2% in the 2nd quarter. UBS Group AG now owns 455,265 shares of the biopharmaceutical company’s stock valued at $1,343,000 after purchasing an additional 423,806 shares during the period.  Finally, Point72 Asset Management L. P. purchased a new position in shares of  CymaBay Therapeutics in the 2nd quarter valued at approximately $1,033,000. Hedge funds and other institutional investors own  73.54% of the company’s stock.

CymaBay Therapeutics, Inc engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.